Westminster, Colorado-based Cerapedics, Inc. has announced the expansion of the company’s headquarters in the Denver metropolitan area. Its facility is going from 14,000 to 24,000 square feet, with an expansion of its global workforce from 32 to 73 employees. In Colorado alone the company has grown from 16 to 44 employees.
Cerapedics Expands Headquarters, Workforce
2 min read Premium comments
Secondary#cerapedics
“We are excited to grow our Colorado footprint and bring more jobs and career opportunities to the Denver area,” said CEO Glen Kashuba. “This expansion allows us to further control our value chain by relocating our distribution activities to our corporate headquarters. We now have the potential to double our headcount across key administrative, operational and sales support departments to meet the growing demand for i-FACTOR Peptide Enhanced Bone Graft and drive the business for years to come.”
In addition, Cerapedics is currently enrolling patients in an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of the next-generation P-15L Peptide Enhanced Bone Graft in transforaminal lumbar interbody fusion (TLIF) surgery.
“We are excited about our future product offering and further advancement of our growing bone graft franchise,” said Edward Sawyer, General Manager and Head of Colorado Operations. “Expanding our facility enables us to double our Colorado staff to best service our customers and our product. We’ve benefited greatly from our Colorado location and are pleased to continue to expand our team of talented professionals. We have found a strong pool of talent upon which to utilize in the Denver Metro Area.”
Regarding details on how they are managing the personnel growth, Sawyer commented to OTW, “We are proactively managing the personnel expansion with a rolling three-month analysis comparing anticipated growth versus calculated efficiency per individual and the onboarding time for key departments. We are hiring at a slight risk in advance of the needs to ensure we don’t lose productivity or decrease the strength of the support we provide to our customers.”
Asked how the company might be one year from now as a result of these changes, he noted, “We expect the headcount to grow an additional 30-40% in Colorado and an additional 20-30% globally in the next 12 months as we continue our current growth trajectory.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.